Cardio Diagnostics, a cardiovascular medicine company, went public via a SPAC merger with Mana Capital Acquisition, a special purposes acquisition vehicle, in a $175m deal. “We are very pleased to have combined with Cardio and created a publicly listed company set to transform cardiovascular disease through epigenetics. Cardio is the first company to develop and commercialize epigenetics-based clinical tests for cardiovascular disease that have clear value for patients, clinicians, hospitals/health systems, and payors,” Jonathan Intrater, Mana Capital Chairman. On August 23, 2022, Mana Capital Acquisition extends period to consummate $175m merger.